Prescribing across borders: a guide for physicians.

This page is written for a treating physician who is considering a cross-border named-patient pathway for a specific patient, and who wants to understand their role, our role, and what the documentation and logistics will actually look like in practice. It is deliberately long, because cross-border prescribing is a field in which the shortcuts are the mistakes, and a careful prescriber will want the full picture before committing their professional judgment to a particular plan of care.

When to consider an international named-patient path

The named-patient pathway exists to give individual patients access to a specific therapy that is not otherwise available in their country of residence, when the treating physician has determined that the therapy is medically necessary for that patient. The typical scenarios are straightforward. The drug is FDA-approved in the United States but not yet registered in the destination country. The drug is registered locally but is in durable shortage, on restricted formulary, or available only in a pack size or presentation that does not match the prescriber's plan. The drug is registered but reimbursement has not been established and the family is prepared to pay privately for faster access. In each of these cases, a named-patient pathway through a US specialty pharmacy can be the right answer, provided the drug is within the scope of our service and the destination country operates a recognizable pathway for the indication in question. When the answer is "not available here," a structured NPP path is often more effective than patient-initiated personal importation; for the contrast, see NPP versus personal importation.

Cases where a named-patient pathway is usually not the right answer are equally clear. The therapy is investigational and not FDA-approved; in that case, the correct route is the manufacturer's Expanded Access program, which the treating physician initiates directly. The patient's clinical situation calls for a therapy that is reasonably available locally; in that case, the local path is simpler and usually appropriate. The indication falls into a category the destination country has closed to NPP import; in that case, we will tell the prescriber at intake, and the path forward is either an alternative therapy or an alternative destination.

The prescriber's role

The treating physician is the decision-maker for the therapy and for the patient's clinical management. We do not prescribe, we do not override a prescriber's judgment, and we do not insert ourselves between the prescriber and the patient. What the prescriber commits to, by agreeing to a named-patient pathway with us, is four specific things: signing a prescription that meets the destination country's requirements, signing a medical-necessity letter that supports the NPP application, remaining the clinical contact for administration and follow-up, and routing any adverse event back through us for pharmacovigilance reporting. None of this displaces the normal prescriber-patient relationship; it extends it across an international logistics layer that we manage.

A prescriber who has never worked with a named-patient coordinator before typically finds the paperwork lighter than they expected and the communication more frequent than they are used to. We communicate at each stage transition rather than at the end, and we ask for prescriber confirmation on the items that require it rather than assume authority we do not have. The right cadence, in our experience, is a brief check-in at order placement, a confirmation at shipment, and a handoff note at receipt.

Our role, in one paragraph

Reserve Meds is a brand operated by Altima Care, a US-licensed specialty wholesaler. We source through DSCSA-compliant US specialty wholesalers, we perform clinical and regulatory review on every case before any unit ships, we dispense through a licensed US pharmacist-in-charge at Altima Care, we coordinate the cold-chain logistics and the destination customs clearance, and we remain engaged through the first follow-up cycle after the patient has been treated. We do not prescribe, we do not dispense outside the US pharmacy framework, and we do not operate in channels we cannot document.

Documentation the prescriber will produce

The prescriber produces three documents on the typical case. The first is the prescription itself, in a format acceptable to the destination country's named-patient pathway. Requirements vary: some destinations accept a standard US prescription with an apostilled signature; others require a prescription issued on the prescriber's local letterhead with the prescriber's local license number; others require the prescription to be routed through a local hospital pharmacy's order system. Our regulatory review will tell the prescriber which form applies, and we provide a template where useful. The second is the medical-necessity letter. This is a short statement, typically one to two pages, that identifies the patient, describes the indication, summarizes the treatment rationale, states why locally available alternatives are inadequate, and confirms the prescriber's commitment to ongoing clinical management. We provide a medical-necessity letter template to reduce the drafting burden. The third is the patient consent. We provide a named-patient consent template that covers the cross-border NPP pathway, the cold-chain logistics, and the pharmacovigilance obligations; the prescriber or the hospital's compliance officer should adapt it for local law before use.

How adverse-event reporting flows back

If an adverse event is observed after administration, the prescriber reports it to us at [email protected], and we report forward. Serious adverse events are reported to the FDA MedWatch program, to the manufacturer's global safety group where relevant, and to the destination country's regulator where local rules require a prescriber-side filing in parallel. Our pharmacovigilance team prepares the filings and shares them with the prescriber for review where the prescriber is a co-reporter. The chain of custody we maintain for every unit makes adverse-event causality assessment materially easier than it would be for product from an undocumented channel.

Refills and next cycles

For multi-cycle therapies, we typically open a lightweight recurring case after the first administration. Subsequent cycles move through a shorter cycle-specific review rather than a fresh intake, and the prescriber confirms the next cycle's prescription and timing. If the prescriber elects to adjust the regimen mid-course, we re-enter clinical review for the adjusted plan before sourcing the next unit; if the adjustment is straightforward, the re-review is quick. What we do not do is fill an adjusted regimen on the strength of the original prescription alone; the adjustment carries its own review.

What a prescriber should expect on timeline

A typical specialty case from intake to delivery runs two to four weeks, and a typical cycle refill runs one to two weeks once the recurring case is open. Complex cases with ultra-cold or cryogenic logistics run longer, and destinations with longer regulatory windows extend the timeline accordingly. We quote a specific window at intake, we communicate if the window slides, and we do not quote aggressive best-case windows we are unlikely to deliver.

Confidentiality and the case record

The case record is available to the prescriber on request at any point during and after the case. Patient information is handled under HIPAA and, where the patient has an EU nexus, under GDPR; materials are retained only for the period regulatory obligations require and are not shared outside the review team. For institutional prescribers, the case record can be routed into the institution's medical records system on request.

Practical first step for a prescriber

A prescriber considering a first named-patient case with us can start with a short written note describing the patient in general terms, the drug under consideration, and the destination. We will return an initial feasibility signal within one business day and identify the specific documentation we would need to proceed. No commitment attaches to the inquiry; the coordination fee attaches only when the case moves into active coordination. For the specific intake channel, see the consultation page, or email the prescriber team directly at [email protected].

Reviewed 2026-04-22 by Reserve Meds’s AI clinical and regulatory review agents. Human pharmacist-in-charge: Altima Care. Next scheduled review: 2026-10-22.